Nat. Biotechnol. 23, 529–530 (2005)
On page 528, an imaging agent, Prussian Blue, was mistakenly included in the NME totals for 2003. Thus, in Table 1 and corresponding places in the text, the total number of NMEs approved in 2003 should be reduced from 21 to 20 and the total number of new drugs from 27 to 26. The totals for the 6-year period should be similarly reduced from 145 to 144 for total NMEs and from 171 to 170 for total drugs. Also, the NME Somavert originated in Ohio University, which then licensed rights to Genentech. Thus, the number of university inventions should be increased from 3 to 4 for 2003, and from 20 to 21 for the entire 6-year period.
Additional information
The online version of the original article can be found at 10.1038/nbt0505-529
Rights and permissions
About this article
Cite this article
Kneller, R. Correction: Corrigendum: The origins of new drugs. Nat Biotechnol 23, 1018 (2005). https://doi.org/10.1038/nbt0805-1018c
Issue Date:
DOI: https://doi.org/10.1038/nbt0805-1018c
